Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus
Authors:
- 28 January 2016
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 76 (3) , 363-374
Abstract
Insulin glargine 300 U/mL (Toujeo®) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus®), with a duration of glucose-lowering activity exceeding 24 h. In several 6-month phase III trials, insulin glargine 300 U/mL achieved comparable glycaemic control to that seen with insulin glargine 100 U/mL in patients with type 1 or type 2 diabetes, albeit with consistently higher daily basal insulin requirements. These improvements in glycaemic control were maintained during longer-term (12 months) treatment. Insulin glargine 300 U/mL was generally associated with a lower risk of nocturnal hypoglycaemia than insulin glargine 100 U/mL in insulin-experienced patients with type 2 diabetes, while the risk of nocturnal hypoglycaemia did not significantly differ between treatment groups in insulin-naïve patients with type 2 diabetes or in patients with type 1 diabetes. To conclude, once-daily subcutaneous insulin glargine 300 U/mL is an effective and generally well tolerated basal insulin therapy option for patients with type 1 or type 2 diabetes.Keywords
This publication has 23 references indexed in Scilit:
- Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetesDiabetes, Obesity and Metabolism, 2014
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)Diabetes Care, 2014
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)Diabetes Care, 2014
- New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1Diabetes Care, 2014
- The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Expert Opinion on Biological Therapy, 2014
- Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/mlDiabetes, Obesity and Metabolism, 2014
- Basal insulin analogues in the management of diabetes mellitus: what progress have we made?Diabetes/Metabolism Research and Reviews, 2014
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects*Diabetes, Obesity and Metabolism, 2008
- Insulin GlargineDrugs, 2003